NASDAQ: LFST

LifeStance Health (LFST) Stock Analysis & Forecast

Nov 13 close

$14.08−0.07 (−0.5%)

Gekko Brief

AI summaryNov 9 close

LifeStance Health moves this week on strong third-quarter results, with revenue and EBITDA exceeding consensus and management raising its full-year outlook; BMO Capital responded by lifting its price target to $16.00 from $13.00 while maintaining an Outperform rating. Alongside the results, the company guided 2027 growth toward the low end of its mid-teens long-term range, citing a new EHR system transition expected to weigh on growth by 1 to 2 percentage points. The company also launched and priced a secondary public offering of 45,000,000 shares, in which existing stockholders are selling and the company receives no proceeds.

Shares close at $14.60, up 6% on the day, sitting above both the 50-day average of $12.66 and the 200-day average of $9.53, with a 52-week high of $15.66 reached recently. The GekkoIndex reads 44.7, placing the stock in the Distribution zone. Gekko Fair Value stands at $15.1, putting the current price about 3.3% below that mark.

Earnings are not due until 24 February 2027, 106 days out, placing the next report outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point has averaged -7.9% over the next 20 trading days across 5 years, with gains in 3 of them, a mixed signal worth weighing against the current momentum and analyst consensus, which stands at 9 buy and 1 hold among 10 firms with a consensus target of $14.45.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

LifeStance Health price vs fair value

$15.77$14.08Nov ’25May ’26Nov ’26
Close $14.08200-day averageGekko Fair Value $15.77

LifeStance Health quick facts

Market cap
$5.35B
P/E ratio
78.6
Forward P/E
62.5
EPS, TTM
$0.18
Revenue, TTM
$1.68B
Profit margin
4.3%
Dividend yield
—
Beta
1.30
Volume
3.73M avg 6.64M
1-year return
+118.6%
Typical daily move
±5.4%
Typical 20-day move
±10.1%
50-day average
$12.79
200-day average
$9.67
Next earnings
Feb 24 before open
Shares outstanding
380.2M
52-week range
$6.02$15.66

LifeStance Health swing-trade checklist

LifeStance Health scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $14.08 is above the 50-day ($12.79) and 200-day ($9.67) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    50.3, Neutral

    Reading 50.3 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    10.7% below

    Price is 10.7% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −0.4% on average

    From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

LifeStance Health stock chart and price history

LifeStance Health closed at $14.08 on Nov 13, 2026, +118.6% over the past year, inside a 52-week range of $6.02 to $15.66.

Close50-day average200-day averageVolume
LifeStance Health share price, past year, with 50-day and 200-day moving averages and volume$6$8$10$12DecJan 2026FebMarAprMayJunJulAugSepOctNov14.08

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+13.8%
3 months
+12.2%
6 months
+84.1%
1 year
+118.6%
The full LFST chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LFST in Gekko

Follow LifeStance Health through every session

Put LFST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track LFST in GekkoFree for 7 days. No credit card required.

About LifeStance Health

LifeStance Health operates a network of affiliated practices focused on outpatient mental health care. Clinicians within this network handle psychiatric evaluations, prescribe and manage treatment, run psychological and neuropsychological assessments, and lead sessions that may involve a single patient, a family unit, or a small group. The conditions treated span common struggles like anxiety and depression as well as more difficult diagnoses such as bipolar disorder, eating disorders, psychosis, and post-traumatic stress.

Patients can choose between visiting one of the physical locations or connecting with a provider remotely through a virtual option. The practices under LifeStance serve people at every stage of life, from young children through elderly adults, with a physical footprint spread across 32 states.

LifeStance Health traces its founding to 2017 and runs its headquarters out of Scottsdale, Arizona. The company trades on the NASDAQ under the ticker LFST.

Listed
NASDAQ
Sector
Health services
Industry
Medical/Nursing services
Website
lifestance.com

LifeStance Health GekkoIndex: the smart money zone

LifeStance Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.3, in the Neutral zone, up 1.4 points over five sessions.

010050.3Neutral

Up 1.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying44+1.1%+1.1%+5.7%+3.8%
Accumulation207+1.4%+1.7%+3.5%+3.5%
Neutral (current zone)399+0.3%+1.7%+2.9%+9.2%
Distribution51+1.3%−0.3%−0.6%+9.9%
Selling1Too few readings yet

Average LFST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the LFST price, zone by zone.Track LFST in Gekko

Is LifeStance Health stock overvalued? Gekko Fair Value

LifeStance Health trades 10.7% below Gekko Fair Value of $15.77, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what LifeStance Health shares are worth, recalculated every trading day.

$15.77

Gekko Fair Value, Nov 14, 2026

10.7% Undervalued

At the end of Aug 2026 the price was 18.2% below the estimate.

Gekko Fair ValueShare price, month end
$16$14Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open LFST in Gekko

LifeStance Health insider and Congress trading

No open-market insider purchases were filed for LifeStance Health, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for LFST in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every LFST insider filing, plotted on the chart in Gekko.Open LFST in Gekko

Congress trades last 90 days

No trades in LFST were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for LFST, plotted on the chart in Gekko.Open LFST in Gekko

Buybacks

LifeStance Health has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$24.81M
As a share of market cap
0.46%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold LFST.

0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko

LifeStance Health earnings: next date and track record

LifeStance Health reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±9.1%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

+3.2%Nov ’24+3.7%Feb ’25−11.3%May ’25+12.1%Aug ’25+30.8%Nov ’25−2.5%Feb ’26+4.6%May ’26+4.5%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
LifeStance Health delivered Q2 2026 revenue growth exceeding 26% with adjusted EBITDA margins above 15%, surpassing all guided metrics. The clinician base grew to over 8,500 providers with strong productivity. The company expanded TMS and Spravato specialty services, completed a tuck-in acquisition in Arizona, and is preparing for a new EHR system transition in 2027. Clinical outcomes data showed 75%+ of patients achieved meaningful improvement across diverse populations.
Guidance
Management raised full year 2026 guidance across all metrics following Q2 outperformance. The company plans continued geographic expansion into new markets, targeting roughly half of the 150 largest U.S. markets where no presence currently exists, with tuck-in acquisitions as the preferred growth vehicle.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$0.06
est $0.03
+100.0%$435.4M
est $414.6M
+5.0%+4.5%
May 7, 2026$0.07
est $0.06
+10.4%$403.5M
est $387.5M
+4.1%+4.6%
Feb 25, 2026$0.09
est $0.05
+64.4%$382.2M
est $378.4M
+1.0%−2.5%
Nov 6, 2025$0.00
est −$0.01
+127.7%$363.8M
est $378.5M
−3.9%+30.8%
Aug 7, 2025−$0.01
est −$0.03
+66.7%$345.3M
est $358.4M
−3.6%+12.1%
May 7, 2025$0.05
est $0.01
+400.0%$333.0M
est $348.7M
−4.5%−11.3%
Feb 27, 2025−$0.01
est −$0.04
+73.9%$325.5M
est $333.4M
−2.4%+3.7%
Nov 7, 2024−$0.02
est −$0.07
+71.4%$312.7M
est $314.0M
−0.4%+3.2%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

LifeStance Health stock forecast and analyst price targets

Analysts’ average 12-month price target for LifeStance Health is $16.80, +19.3% from the last close, from 10 firms rating the stock in the last 90 days.

$16.80consensus 12-month target, +19.3% from the last close
Low $15High $20
Buy9
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12J.P. MorganHold, maintained$15+6.5%
Nov 11BarclaysBuy, reiterated$18+27.8%
Nov 11BarclaysBuy, maintained$18+27.8%
Nov 9UBSBuy, maintained$19+34.9%
Nov 6BarclaysBuy, maintained$15+6.5%
+2.9%average 20-day move after past Neutral readings
−0.4%average move over the next 20 trading days in the last 5 years
±5.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

LifeStance Health seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, LifeStance Health averaged −0.4% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−9.1%2021−14.7%2022+13.5%2023−0.8%2024+8.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−7.7%1 of 5
Next 10 trading days−7.3%3 of 5
Next 15 trading days−2.5%2 of 5
Next 20 trading days−0.4%2 of 5
Next 30 trading days+0.6%3 of 5

For scale, LFST’s typical 20-trading-day move in either direction is about 10.1%.

LifeStance Health market cap and key statistics

LifeStance Health’s market cap is $5.35B, with a P/E ratio of 78.6 and revenue of $1.68B over the last twelve months.

Valuation

Market cap
$5.35B
P/E ratio
78.6
Forward P/E
62.5
EPS, TTM
$0.18
Gekko Fair Value
$15.77

Trading

Volume
3.73M
Avg volume, 20 days
6.64M
52-week high
$15.66
52-week low
$6.02
Shares outstanding
380.2M

Financials

Revenue, TTM
$1.68B
Profit margin
4.3%
Return on equity
4.8%
Quarterly earnings growth, YoY
+2,021.0%

Risk and income

Beta
1.30
Typical daily move
±5.4%
Typical 20-day move
±10.1%

LifeStance Health peers

LifeStance Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
ENSGEnsign+0.3%Neutral15.6% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

LifeStance Health stock FAQ

What is LifeStance Health’s market cap?

LifeStance Health’s market cap is $5.35B at the Nov 13, 2026 close of $14.08, with 380.2M shares outstanding. The shares trade on a P/E ratio of 78.6.

What is the LifeStance Health stock forecast?

The consensus analyst 12-month price target for LifeStance Health is $16.80, +19.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 9 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is LifeStance Health stock overvalued or undervalued?

On Gekko’s estimate LifeStance Health is undervalued: the Nov 13, 2026 close of $14.08 is 10.7% below Gekko Fair Value of $15.77. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does LifeStance Health report earnings next?

LifeStance Health is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of $0.04 per share on revenue of $454.7M. LifeStance Health beat the earnings estimate in 8 of its last 8 reports, moving 9.1% on average across the report.

What is LifeStance Health’s 52-week high and low?

LifeStance Health’s 52-week high is $15.66 and its 52-week low is $6.02; it closed at $14.08 on Nov 13, 2026, +118.6% over the past year.

Is LifeStance Health stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See LifeStance Health the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.